$101.9 B

GSK.L Mkt cap, 11-Jul-2018

£7.2 B

GlaxoSmithKline Revenue Q1, 2018
GlaxoSmithKline Gross profit (Q1, 2018)4.8 B
GlaxoSmithKline Gross profit margin (Q1, 2018), %66.9%
GlaxoSmithKline Net income (Q1, 2018)759 M
GlaxoSmithKline EBIT (Q1, 2018)1.2 B
GlaxoSmithKline Cash, 31-Mar-20184 B
GlaxoSmithKline EV115.4 B

GlaxoSmithKline Revenue

GlaxoSmithKline revenue was £30.19 b in FY, 2017 which is a 8.2% year over year increase from the previous period.

Embed Graph

GlaxoSmithKline Revenue Breakdown

Embed Graph

GlaxoSmithKline revenue breakdown by business segment: 25.7% from Consumer Healthcare, 17.1% from Vaccines and 57.2% from Global Pharmaceuticals

GlaxoSmithKline revenue breakdown by geographic segment: 59.6% from International, 37.3% from US and 3.1% from Other

GlaxoSmithKline Income Statement

Annual

GBPFY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2013FY, 2016FY, 2017

Revenue

18.1b20.5b21.2b21.4b20.4b21.7b23.2b22.7b26.5b27.9b30.2b

Revenue growth, %

17%8%

Cost of goods sold

4.0b4.7b4.6b4.5b4.3b4.8b5.0b5.3b8.6b9.3b10.3b

Gross profit

14.1b15.8b16.6b16.9b16.0b16.9b18.2b17.4b17.9b18.6b19.8b

Gross profit Margin, %

78%77%78%79%79%78%78%77%68%67%66%

R&D expense

3.6b4.5b

General and administrative expense

9.4b9.7b

Operating expense total

9.4b11.0b11.1b10.5b10.0b10.0b10.4b9.8b10.9b16.0b15.8b

EBITDA

8.7b9.3b

EBITDA margin, %

38%35%

EBIT

4.7b4.7b5.6b6.4b6.1b6.9b7.8b7.6b7.0b2.6b4.1b

EBIT margin, %

26%23%26%30%30%32%34%33%27%9%14%

Interest expense

736.0m734.0m

Interest income

72.0m65.0m

Pre tax profit

6.0b4.5b5.5b6.3b6.1b6.7b7.8b7.5b6.6b1.9b3.5b

Income tax expense

(1.7b)(1.3b)(1.5b)(1.7b)(1.7b)(1.9b)(2.3b)(2.1b)(1.0b)877.0m1.4b

Net Income

4.3b3.2b4.0b4.6b4.4b4.8b5.5b5.3b5.6b1.1b2.2b

Quarterly

GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

7.4b7.3b7.8b7.2b

Cost of goods sold

2.5b2.6b2.7b2.4b

Gross profit

4.9b4.7b5.2b4.8b

Gross profit Margin, %

66%64%66%67%

R&D expense

960.0m1.3b1.0b904.0m

General and administrative expense

2.5b2.4b2.3b2.3b

Operating expense total

3.2b4.7b3.3b3.6b

EBIT

1.7b(20.0m)1.9b1.2b

EBIT margin, %

23%0%24%17%

Interest expense

194.0m192.0m194.0m162.0m

Interest income

21.0m15.0m13.0m20.0m

Pre tax profit

1.6b(178.0m)1.7b1.1b

Income tax expense

327.0m(92.0m)316.0m348.0m

Net Income

1.2b(86.0m)1.4b759.0m

GlaxoSmithKline Balance Sheet

Annual

GBPFY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2013FY, 2016FY, 2017

Cash

1.3b716.0m1.1b962.0m1.2b4.2b2.0b3.4b5.5b4.9b3.8b

Accounts Receivable

3.3b3.6b3.5b3.7b3.8b4.4b4.4b4.6b4.0b6.0b6.0b

Inventories

2.3b2.1b2.1b2.1b2.2b2.2b2.4b3.1b3.9b5.1b5.6b

Current Assets

11.3b10.0b10.7b12.6b13.6b13.2b11.0b13.6b15.2b16.7b15.9b

PP&E

9.2b10.1b9.8b9.5b6.8b9.9b10.5b7.8b8.9b10.8b10.9b

Goodwill

6.0b5.7b

Total Assets

21.6b21.9b22.3b24.0b22.6b27.2b25.6b31.0b42.1b59.1b56.4b

Accounts Payable

812.0m760.0m715.0m686.0m707.0m819.0m865.0m931.0m2.7b12.0b21.0b

Short-term debt

4.1b2.8b

Current Liabilities

9.1b9.4b8.8b8.6b8.7b9.5b7.3b10.3b13.7b19.0b26.6b

Long-term debt

14.7b14.3b

Non-Current Liabilities

4.8b5.0b6.9b7.7b7.9b10.4b8.9b11.1b21.4b35.1b26.3b

Total Debt

191.0m230.0m193.0m155.0m112.0m1.1b676.0m3.5b2.8b18.8b17.1b

Total Liabilities

13.9b14.4b15.7b16.3b16.7b19.9b16.2b21.4b35.1b54.1b52.9b

Common Stock

1.3b1.3b

Additional Paid-in Capital

1.6b1.5b1.5b1.5b1.5b1.5b1.5b1.5b1.3b3.0b3.0b

Retained Earnings

4.2b703.0m1.6b2.1b1.9b2.3b2.8b2.4b1.9b(5.4b)(6.5b)

Total Equity

7.7b7.5b6.6b7.7b5.9b7.3b9.4b9.6b7.0b5.0b3.5b

Debt to Equity Ratio

0 x0 x0 x0 x0 x0.2 x0.1 x0.4 x0.4 x3.8 x4.9 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0.1 x0.1 x0.3 x0.3 x

Financial Leverage

2.8 x2.9 x3.4 x3.1 x3.8 x3.7 x2.7 x3.2 x6 x11.9 x16.2 x

Quarterly

GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

4.5b4.0b4.7b4.0b

Accounts Receivable

6.2b6.2b6.5b6.1b

Inventories

5.4b5.7b5.7b5.7b

Current Assets

16.8b16.4b17.7b16.4b

PP&E

10.8b10.7b10.6b10.7b

Goodwill

6.0b5.9b5.8b5.6b

Total Assets

59.2b58.2b5.9b56.2b

Accounts Payable

12.0b19.6b19.8b21.1b

Short-term debt

3.7b6.6b4.7b3.4b

Current Liabilities

18.8b28.8b27.4b26.9b

Long-term debt

14.6b12.3b14.3b14.0b

Non-Current Liabilities

34.9b25.0b26.5b25.6b

Total Debt

18.3b18.9b19.0b17.5b

Total Liabilities

53.6b53.8b54.0b52.6b

Common Stock

1.3b1.3b1.3b1.3b

Additional Paid-in Capital

3.0b3.0b3.0b3.0b

Retained Earnings

(4.9b)(5.9b)(5.3b)(6.4b)

Total Equity

5.6b4.4b4.8b3.6b

Debt to Equity Ratio

4.3 x3.9 x4.9 x

Debt to Assets Ratio

0.3 x3.2 x0.3 x

Financial Leverage

10.6 x13.2 x1.2 x15.6 x

GlaxoSmithKline Cash Flow

Annual

GBPFY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2013FY, 2016FY, 2017

Net Income

4.3b3.2b4.0b4.6b4.4b4.8b5.5b5.3b5.6b1.1b2.2b

Depreciation and Amortization

2.0b2.9b

Accounts Receivable

(188.0m)(287.0m)

Inventories

70.0m(461.0m)

Accounts Payable

96.0m11.0m

Cash From Operating Activities

5.4b6.5b7.3b7.0b6.5b6.0b4.4b6.2b7.2b6.5b6.9b

Purchases of PP&E

(1.5b)(1.5b)

Cash From Investing Activities

(1.3b)(1.4b)

Short-term Borrowings

148.0m(3.2b)

Long-term Borrowings

(18.0m)(23.0m)

Dividends Paid

56.0m2.4b2.4b2.4b2.4b2.4b2.6b2.8b3.7b(4.8b)(3.9b)

Cash From Financing Activities

(546.0m)(1.4b)(1.6b)(276.0m)(454.0m)(2.9b)(4.8b)(1.7b)(6.3b)(6.4b)(6.4b)

Net Change in Cash

822.0m612.0m405.0m27.0m257.0m1.4b2.0b1.4b1.5b(1.2b)(905.0m)

Interest Paid

(732.0m)(781.0m)

Income Taxes Paid

(1.6b)(1.3b)

Quarterly

GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

1.2b1.1b2.5b759.0m

Cash From Operating Activities

1.1b2.2b4.0b863.0m

Purchases of PP&E

(260.0m)(639.0m)(1.0b)(258.0m)

Cash From Investing Activities

(199.0m)(646.0m)(1.1b)(371.0m)

Short-term Borrowings

(528.0m)386.0m(1.4b)701.0m

Long-term Borrowings

(3.0m)(13.0m)(18.0m)(7.0m)

Dividends Paid

(925.0m)(2.0b)(3.0b)(929.0m)

Cash From Financing Activities

(1.5b)(2.5b)(3.1b)(283.0m)

Net Change in Cash

(564.0m)(968.0m)(182.0m)209.0m

Income Taxes Paid

(206.0m)(557.0m)(893.0m)(198.0m)

GlaxoSmithKline Ratios

GBPY, 2018

EV/EBIT

93 x

EV/CFO

133.7 x

Debt/Equity

4.9 x

Debt/Assets

0.3 x

Financial Leverage

15.6 x
Report incorrect company information

GlaxoSmithKline Operating Metrics

GlaxoSmithKline's Unique Visitors was reported to be 1.8 m in FY, 2015.
FY, 2014FY, 2015FY, 2016FY, 2017

Consumer Healthcare Products Produced

6.20 b

Countries

100 100 100

Manufacturing Facilities

57 54 87

Markets

150 150 150

New Product Launches

50 40 30

Partners

1.50 k1.50 k2 k

Unique Visitors

1.80 m

Vaccine Doses Delivered per Day

2 m

Vaccines

798 m

Volume of Medicines Produced

1.90 b
Report incorrect company information